





Dr Faiza Gaba MBBS, MRCOG

Clinical Trial Co-ordinator & Registrar Obstetrics & Gynaecology (ST4)

Dr Ranjit Manchanda MD, MRCOG, PhD
Chief Investigator & Consultant Gynaecological Oncologist

On behalf of the PROTECTOR team





## **BACKGROUND**

| Barts | Cancer Institute | tues | terr | Institute









#### **ONS/NRS/HESA statistics:**

2014 (UK): 361,216 new cancers vs 289,841 marriages (ONS/NRS)

Just as likely to graduate from university as you are to get cancer (HESA)





Europe

UK

65584

74982

14% ↑

27% 个

2012

2035

### **Ovarian Cancer Deaths**

42749

52419

22% 个

36% 个

2012

2035






# Age standardised 10 year survival in OC, England & Wales



#### Ovarian Cancer (C56 C57.0-C57.7): 1971-2011





**Age-Standardised Ten-Year Net Survival, England and Wales** 






| Barts | Cancer Institute The approach over the last 30 years has resulted in only small improvements in impact on burden of disease!






# Risk Reducing Salpingo-oophorectomy













history of BC

# Risk Reducing Early Salpingectomy With Delayed Oophorectomy

**BENEFITS** 

Allows women who wish to delay surgical prevention to have some OC risk reduction

Retain natural hormones for longer

Avoid 'detrimental' consequences of early menopause







#### **LIMITATIONS**

Removing the tube will not prevent all OC

Precise level of benefit not well quantified

Need better understanding of implications on long term health







Two operations instead of one

Concerns amongst some clinicians that some women who have ES may not go on to have DO – it is important that everyone does







## **PROTECTOR**










27 recruitment sites across UK

Participants can choose which arm they wish to participate in











**Evaluate Early Salpingectomy (early removal of tubes) by comparing outcomes between all 3 approaches** 















# Who can take part in PROTECTOR?



HIGH RISK for Ovarian Cancer

Strong family history of ovarian cancer which will warrant surgical prevention

**Premenopausal ≥30years** 

**Completed family (for surgical arms)** 





# Who Cannot take part in PROTECTOR



Previous operation to remove both fallopian tubes or both ovaries	
Postmenopausal	
Pregnancy	]
	•
Clinical suspicion of tubal/ovarian cancer at baseline	
	1
Unable to provide informed consent	_



#### Recruitment




Clinics: NHS cancer genetics; high-risk familial cancer clinics; general gynaecology clinics; gynaecological oncology clinics **GP-surgeries Self-referral Supporting charities** 










## **Recruitment Target**





Study in set up phase

Anticipated start date: ~ May 2018





#### **Collaborators**



**Usha Menon** 

**Gareth Evans** 

Naveena Singh

**Glen McCluggage** 

**Ertan Saridogan** 

**Marc Tischkowitz** 

**Robin Crawford** 

**Matthew Burnell** 

**Rosa Legood** 

Ajith Kumar

Lucy Side

Raji Ganesan

Ian Hartley

Asma Faruqi

Munaza Ahmed

Angela Brady

Sadaf Ghaem-Maghami

Vishakha Tripathi

Aarti Sharma

Rekha Wuntakal

**Gautam Mehra** 

**Dorothy Halliday** 

**Helen Hanson** 

Katie Snape

**Anil Tailor** 

**Ahmed Ahmed** 

Tom Ind

Ketan Gajjar

Sudha Sundar

Raj Naik

Sonali Kaushik

Mahalakshmi Gurumurthy

Rema Iyer

Tim Duncan

**Robert Woolas** 

Nafisa Wilkinson

Wendy McMullen

Kalpana Ragupathy

Please contact us if you are interested in taking part in the study:

f.gaba@qmul.ac.uk r.manchanda@qmul.ac.uk







# Thank you





Please contact us if you are interested in taking part in the study:

f.gaba@qmul.ac.uk r.manchanda@qmul.ac.uk